[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333340-105":59,"doc-detail-333340-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-interleukin-6-as-a-treatment-approach-for-peritoneal-carcinomatosis","Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis","","Peritoneal carcinomatosis (PC) is a complex manifestation of abdominal cancers, with poor prognosis and limited treatment options. High concentrations of interleukin-6 (IL-6) and its soluble receptor (sIL-6-Rα) in the peritoneal cavity suggest this pathway as an emerging therapeutic target. This review summarizes IL-6 contributions to tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and immune modulation, and evaluates prospects for IL-6 pathway targeting across cancer origins.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-interleukin-6-as-a-treatment-approach-for-peritoneal-carcinomatosis/333340/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-interleukin-6-as-a-treatment-approach-for-peritoneal-carcinomatosis/333340.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the key therapeutic rationale for targeting IL-6 in peritoneal carcinomatosis (PC)?","Question",{"text":112,"@type":113},"The review highlights high concentrations of IL-6 and its soluble receptor (sIL-6-Rα) in the peritoneal cavity of PC patients, supporting the IL-6 pathway as a potential therapeutic target.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How might the IL-6 pathway contribute to PC progression according to the review?",{"text":117,"@type":113},"It may drive peritoneal tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and modulation of the immune response.",{"name":119,"@type":110,"acceptedAnswer":120},"Which treatment types are discussed as existing options for PC and what limitation is emphasized?",{"text":121,"@type":113},"Systemic chemotherapy and cytoreductive surgery are described as standard but limited by toxicity and recurrence being the rule. Intraperitoneal chemotherapy has theoretical advantages, yet evidence for improved oncologic outcomes is mixed.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},333340,1790051236,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Dadgar etal. Journal of Translational Medicine (2024) 22:402  \n[https://doi.org/10.1186/s12967-024-05205-8](https://doi.org/10.1186/s12967-024-05205-8)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nTargeting interleukin-6 as a treatment approach for peritoneal carcinomatosis  \nNeda Dadgar 1, Christopher Sherry2, Jenna Zimmerman2, Hyun Park2, Catherine Lewis2, Albert Donnenberg2, Ali H. Zaidi2, Yong Fan2, Kunhong Xiao3, David Bartlett2, Vera Donnenberg4 and Patrick L. Wagner2*  \nAbstract  \nPeritoneal carcinomatosis (PC) is a complex manifestation of abdominal cancers, with a poor prognosis and limited treatment options. Recent work identifying high concentrations of the cytokine interleukin-6 (IL-6) and its soluble receptor (sIL-6-Rα) in the peritoneal cavity of patients with PC has highlighted this pathway as an emerging potential therapeutic target. This review article provides a comprehensive overview of the current understanding of the potential role of IL-6 in the development and progression of PC. We discuss mechansims by which the IL-6 pathway may contribute to peritoneal tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and immune response modulation. Finally, we review the prospects for targeting the IL-6 pathway in the treatment of PC, focusing on common sites of origin, including ovarian, gastric, pancreatic, colorectal and appendiceal cancer, and mesothelioma.  \nKeywords IL-6, Peritoneal carcinomatosis, Targeted therapy, Tumor immune microenvironment  \nBackground  \nPeritoneal carcinomatosis (PC) is a late manifestation of abdominopelvic malignancies, commonly associated with gastrointestinal and gynecological cancers, such as ovarian, colorectal, and pancreatic cancer [1, 2]. Marked by poor prognosis and limited treatment options, PC causes severe symptoms related to intestinal obstruction and nutritional compromise. Treatment is generally  \n*Correspondence:  \nPatrick L. Wagner  \n[patrick.wagner@ahn.org](patrick.wagner@ahn.org)  \n1Translational Hematology & Oncology Research, Enterprise Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, USA  \n2Allegheny Health Network Cancer Institute, 314 E. North Ave, Pittsburgh, PA 15212, USA  \n3Center for Proteomics & Artificial Intelligence, Center for Clinical Mass Spectrometry, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA  \n4University of Pittsburgh School of MedicineDepartment of Cardiothoracic SurgeryUPMC Hillman Cancer Center Wagner, Patrick; Allegheny Health Network Cancer Institute, Pittsburgh, USA  \nconsidered palliative, as disease recurrence is the rule rather than the exception. Coventional treatment modalities include systemic chemotherapy as well as cytoreductive surgery, both of which are plagued with limited efficacy and significant toxicity. Intraperitoneal chemotherapy holds theoretical advantages in selected patients, although there is mixed evidence regarding its contribu  \ntion to oncologic outcome in most cancer types [3–6].  \nGiven the limitations of conventional modalities in treating PC, there is a pressing need to develop novel and innovative strategies for this metastatic pattern. Immunotherapy presents an obvious candidate approach, to which the peritoneal space may be well suited as a distinct immune environment segrated from the systemic circulation. Regional immunotherapy directed toward the peritoneal cavity has been explored as a an alternative strategy to systemic therapy and complementaty to cytoreductive surgery. Such strategies include the use of cytokines, monoclonal antibodies, immune checkpoints, vaccines, viral oncotherapy and adoptive cellular  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link ","cbCaipTIK4Q9Gztp","https://ap.wps.com/l/cbCaipTIK4Q9Gztp","pdf",3090080,18,"English","# Abstract\n# Background\n## Conventional treatment challenges\n## Regional immunotherapy rationale\n## IL-6 pathway as a target","[{\"question\":\"What is the key therapeutic rationale for targeting IL-6 in peritoneal carcinomatosis (PC)?\",\"answer\":\"The review highlights high concentrations of IL-6 and its soluble receptor (sIL-6-Rα) in the peritoneal cavity of PC patients, supporting the IL-6 pathway as a potential therapeutic target.\"},{\"question\":\"How might the IL-6 pathway contribute to PC progression according to the review?\",\"answer\":\"It may drive peritoneal tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and modulation of the immune response.\"},{\"question\":\"Which treatment types are discussed as existing options for PC and what limitation is emphasized?\",\"answer\":\"Systemic chemotherapy and cytoreductive surgery are described as standard but limited by toxicity and recurrence being the rule. Intraperitoneal chemotherapy has theoretical advantages, yet evidence for improved oncologic outcomes is mixed.\"}]","Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis | PDF",1790002044,45]